A Proteome-Derived Longitudinal Pharmacodynamic Biomarker for Diffuse Systemic Sclerosis Skin.

[1]  R. Tibshirani.  Regression Shrinkage and Selection via the Lasso , 1996 .

[2]  M. Hasegawa,et al.  Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. , 2001, Journal of dermatological science.

[3]  S. Dupont,et al.  Links between Tumor Suppressors p53 Is Required for TGF-β Gene Responses by Cooperating with Smads , 2003, Cell.

[4]  K. Miyazono,et al.  Interplay between the tumor suppressor p53 and TGFβ signaling shapes embryonic body axes in Xenopus , 2003, Development.

[5]  S. Dupont,et al.  Convergence of p53 and TGF-beta signaling networks. , 2004, Cancer letters.

[6]  V. Steen.  Autoantibodies in systemic sclerosis. , 1996, Seminars in arthritis and rheumatism.

[7]  C. Denton,et al.  Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. , 2005, Rheumatology.

[8]  M. Hayakawa,et al.  Soluble ST2 Blocks Interleukin-33 Signaling in Allergic Airway Inflammation* , 2007, Journal of Biological Chemistry.

[9]  John Powell,et al.  Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. , 2007, Arthritis and rheumatism.

[10]  R. Lafyatis,et al.  A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. , 2007, Arthritis and rheumatism.

[11]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[12]  A. Kassner,et al.  COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker , 2007, Annals of the rheumatic diseases.

[13]  Sarah A. Pendergrass,et al.  Molecular Subsets in the Gene Expression Signatures of Scleroderma Skin , 2008, PloS one.

[14]  T. Povsic,et al.  Transcriptional Regulation of Bim by FOXO3a and Akt Mediates Scleroderma Serum–Induced Apoptosis in Endothelial Progenitor Cells , 2008, Circulation.

[15]  D. Veale,et al.  Biomarkers in systemic sclerosis. , 2008, Rheumatology.

[16]  S. Abramson,et al.  F-spondin , a neuroregulatory protein , is up-regulated in osteoarthritis and regulates cartilage metabolism via TGF-activation , 2009 .

[17]  P. Shah,et al.  Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis , 2009, European Respiratory Journal.

[18]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[19]  R. Lafyatis,et al.  Poly(I:C) drives type I IFN- and TGFβ-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. , 2010, The Journal of investigative dermatology.

[20]  M. Conforti,et al.  The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis , 2009, Annals of the rheumatic diseases.

[21]  Tracy R. Keeney,et al.  Aptamer-based multiplexed proteomic technology for biomarker discovery , 2010, Nature Precedings.

[22]  R. Lafyatis.  Application of Biomarkers to Clinical Trials in Systemic Sclerosis , 2012, Current Rheumatology Reports.

[23]  Stephen P. Higgins,et al.  TGF-β1 → SMAD/p53/USF2 → PAI-1 transcriptional axis in ureteral obstruction-induced renal fibrosis , 2011, Cell and Tissue Research.

[24]  K. Yanaba,et al.  Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis , 2011, Clinical Rheumatology.

[25]  Peter Langfelder,et al.  Fast R Functions for Robust Correlations and Hierarchical Clustering. , 2012, Journal of statistical software.

[26]  T. Hügle,et al.  T cells in systemic sclerosis: a reappraisal. , 2012, Rheumatology.

[27]  S. Pendergrass,et al.  Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies , 2012, The Journal of investigative dermatology.

[28]  C. Denton,et al.  Biomarkers for skin involvement and fibrotic activity in scleroderma , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[29]  M. Greenblatt,et al.  The Immune Pathogenesis of Scleroderma: Context Is Everything , 2012, Current Rheumatology Reports.

[30]  Y. Yamaguchi,et al.  Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis , 2013, The British journal of dermatology.

[31]  S. Abramson,et al.  F-Spondin Deficient Mice Have a High Bone Mass Phenotype , 2014, PloS one.

[32]  T. Radstake,et al.  Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin , 2013, Annals of the rheumatic diseases.

[33]  L. Joosten,et al.  Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. , 2014, The New England journal of medicine.

[34]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[35]  T. Radstake,et al.  Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic sclerosis phenotype , 2014, Annals of the rheumatic diseases.

[36]  Yasmine Belkaid,et al.  The Alarmin IL-33 Promotes Regulatory T Cell Function in the Intestine , 2014, Nature.

[37]  Guangjie Chen,et al.  Role of IL-33 and Its Receptor in T Cell-Mediated Autoimmune Diseases , 2014, BioMed research international.

[38]  Jürg Schelldorfer,et al.  GLMMLasso: An Algorithm for High-Dimensional Generalized Linear Mixed Models Using ℓ1-Penalization , 2011, 1109.4003.

[39]  C. Denton,et al.  Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial , 2013, Annals of the rheumatic diseases.

[40]  M. Karsdal,et al.  Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis. , 2015, The Journal of investigative dermatology.

[41]  Jeffrey T. Chang,et al.  Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis , 2015, Arthritis & rheumatology.

[42]  M. Whitfield,et al.  A Longitudinal Biomarker for the Extent of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis , 2015, Arthritis & rheumatology.

[43]  M. Whitfield,et al.  Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. , 2015, The Journal of clinical investigation.

[44]  M. Levings,et al.  Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis. , 2015, The Journal of allergy and clinical immunology.